Inmazeb FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 19, 2021.
FDA Approved: Yes (First approved October 14, 2020)
Brand name: Inmazeb
Generic name: atoltivimab, maftivimab, and odesivimab-ebgn
Dosage form: Injection
Company: Regeneron Pharmaceuticals, Inc.
Treatment for: Ebola Zaire Disease Prophylaxis
Inmazeb is (atoltivimab, maftivimab, and odesivimab) is a monoclonal antibody combination indicated for the treatment of Zaire ebolavirus infection in adults and children, including newborns of mothers who have tested positive for the virus.
- The monoclonal antibodies in Inmazeb target the Zaire ebolavirus glycoprotein on the surface of the virus. The antibodies bind to the glycoprotein, blocking its attachment to cell receptors and preventing entry of the virus into the cells.
- Inmazeb is administered as a single intravenous infusion.
- Inmazeb may cause hypersensitivity reactions, including infusion-related events which can be severe or life-threatening. Common adverse events (incidence ≥20%) include pyrexia, chills, tachycardia, tachypnea, and vomiting.
Development Timeline for Inmazeb
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.